Disclaimer: I am not qualified or authorised to give investment advice so please consider taking professional advice before buying the shares.
This company and it’s proprietary blood separation system Parsortix is one I previously wrote about under their previous name Angle PLC. Back then the company was valued at just £30m but has since fallen to just £5m on fears that the company is running out of cash before commercialisation.
However, I feel the early part of this week may present a fantastic opportunity to invest and November and December may prove pivotal in securing a stunningly successful future for CellBXHealth PLC and Parsortix.
There has been some interesting news recently and forthcoming TV and media coverage that suggests CTC capture using Parsortix may be in widespread clinical use within 5 years coupled with imminent much needed funding. Parsortix already has FDA approval for breast cancer and there is a wealth of independent research proving it’s efficacy in a range of cancers.
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology
The paper publishes the consensus of 32 global oncologists and research leaders who agree that CTCs provide unique biological insights not captured by circulating tumour DNA (ctDNA), and that CTCs are poised to transform cancer care through their use in prognosis, treatment monitoring and characterisation to inform precision medicine.
90% of respondents believe that CTCs will become a routine part of clinical practice within the next five years and strongly support their use in metastatic cancer. The publication provides a consensus for the clinical use of CTCs across cancer types, removing the biggest historical barrier of clinical scepticism, and is intended to guide the integration of CTCs into oncologic practice.
Update on Funding
Further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026. CelLBxHealth has recently commenced discussions with a number of shareholders and is seeking to raise approximately £6m with the intention to make an offer to retail investors alongside an institutional placing.
The Company expects to announce the fundraise by early December and will make further updates as appropriate.
In November there is a three part docuseries starting this Thursday 20th at 9pm on the UK’s Channel 4 detailing the work of Prof Caroline Dive at Manchester University on the role of CTC capture and enrichment in lung cancer.
Press Pack Interview with Professor Caroline Dive for Episode 3 | Channel 4
Channel 4 is the most streamed media channel in the UK with 220 million minutes of viewing in October.
Now it appears that Professor Dive may have been using Parsortix since 2016 to do her research work.
Andrew Newland, chief executive, tells Proactive Investors: “This is really important. It comes after four years of working to develop the tests and on the strength of that data they [the University of Manchester] now want to incorporate it for routine use in their clinical laboratory.”
In short then it appears that by the time of the fundraise later this year the company will have had some very significant media exposure and the price at which they can raise money will be a lot higher. Less shareholder dilution and more cash.
The future looks bright here.
I've Got Summink to Say 